Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Connor Clark & Lunn Investment Management Ltd. lessened its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 76.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,327 shares of the life sciences company’s stock after selling 178,735 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.07% of Integra LifeSciences worth $1,277,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in IART. Sachem Head Capital Management LP bought a new stake in Integra LifeSciences in the third quarter worth $44,153,000. Charles Schwab Investment Management Inc. grew its stake in shares of Integra LifeSciences by 10.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company’s stock worth $23,759,000 after buying an additional 103,291 shares in the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Integra LifeSciences by 125.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock worth $13,224,000 after buying an additional 405,624 shares during the last quarter. Systematic Financial Management LP raised its position in shares of Integra LifeSciences by 53.9% during the 3rd quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company’s stock valued at $11,115,000 after buying an additional 214,272 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Integra LifeSciences by 5.5% in the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock valued at $9,603,000 after acquiring an additional 22,000 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley assumed coverage on Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective on the stock. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Stock Up 0.9 %

Shares of NASDAQ IART opened at $22.82 on Thursday. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $35.49. The firm has a 50-day simple moving average of $23.83 and a two-hundred day simple moving average of $22.01. The company has a market cap of $1.76 billion, a P/E ratio of -253.53, a PEG ratio of 0.73 and a beta of 1.23. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $0.89 EPS. Research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.